Comparative Pharmacology
Head-to-head clinical analysis: DEXONE 4 versus H CORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXONE 4 versus H CORT.
DEXONE 4 vs H-CORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a long-acting glucocorticoid receptor agonist, binding to glucocorticoid response elements to modulate gene transcription, resulting in anti-inflammatory, immunosuppressive, anti-allergic, and anti-shock effects.
H-CORT (hydrocortisone) is a corticosteroid with glucocorticoid and mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Oral: 0.75–9 mg/day divided every 6–12 hours; IV/IM: 0.5–9 mg/day divided every 6–12 hours.
Intravenous: 100-250 mg as a single dose or up to 1 gram daily for acute conditions. Oral: 20-30 mg daily in divided doses. Maintenance: 5-20 mg daily.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours (oral); clinical effects persist longer due to glucocorticoid receptor-mediated genomic actions
Terminal elimination half-life: 1.5-2 hours. Clinical context: Short half-life requires q4-6h dosing; duration may be prolonged in hepatic impairment.
Renal excretion of metabolites (<5% unchanged drug); minor biliary/fecal elimination (<1%)
Renal: ~80% as metabolites, ~5% unchanged; biliary/fecal: ~15%
Category C
Category C
Corticosteroid
Corticosteroid